Riou Olivier, Lemanski Claire, Guillaumon Vanessa, Lauche Olivier, Fenoglietto Pascal, Dubois Jean-Bernard, Azria David
Département d'Oncologie Radiothérapie, CRLC Val d'Aurelle-Paul Lamarque, 34298 Montpellier, France.
Int J Surg Oncol. 2012;2012:748196. doi: 10.1155/2012/748196. Epub 2012 Apr 8.
Ductal carcinoma in situ of the breast is associated with low mortality rates, but local relapse is a matter of concern in this disease. Risk factors for local relapse include young age, close or positive margins, and tumor necrosis. Whole breast irradiation following breast-conserving surgery for ductal carcinoma in situ significantly reduces the risk of local relapse as compared to breast-conserving surgery alone. Studies point to similar outcomes between breast-conserving surgery plus radiotherapy and mastectomy, in the absence of extensive disease. A complementary boost to the surgical bed improves outcomes for patients with invasive breast cancer. However, the effect of this strategy has never been prospectively reported for ductal carcinoma in situ. Two randomized controlled trials assessing this issue are ongoing. This paper represents an update on available literature about radiotherapy for DCIS with a special focus on the role of a radiotherapy boost to the tumor bed.
乳腺导管原位癌的死亡率较低,但局部复发是该疾病令人担忧的问题。局部复发的危险因素包括年轻、切缘接近或阳性以及肿瘤坏死。与单纯保乳手术相比,保乳手术后进行全乳放疗可显著降低导管原位癌局部复发的风险。研究表明,在不存在广泛病变的情况下,保乳手术加放疗与乳房切除术的效果相似。对手术床进行补充性加量放疗可改善浸润性乳腺癌患者的预后。然而,对于导管原位癌,这一策略的效果从未有过前瞻性报道。两项评估此问题的随机对照试验正在进行中。本文是关于导管原位癌放疗的现有文献的更新,特别关注对肿瘤床进行放疗加量的作用。